Notifications
Back
Technology
Technology
FNCT BIOTECH is 

advancing a novel antibody-based therapy for pulmonary fibrosis, a disease with significant unmet medical needs. With proof of concept (PoC) established and a clearly defined mechanism of action (MoA), our treatment candidate has demonstrated strong therapeutic potential. Upon successful development, it is poised to become a game changer in pulmonary fibrosis care, offering substantial clinical impact and commercial value. 


"Once fully developed, it is expected to revolutionize pulmonary fibrosis care, delivering significant clinical benefits and strong commercial potential." 

Mode of Action of FB-101
The current paradigm of fibrosis mechanism
  • TGF-β, a widely recognized key regulator of fibrosis, is a primary target in developing antifibrotic therapies
  • For these reasons, various molecules that mediate downstream signaling of TGF-β have also emerged as important targets for anti-fibrotic drug development.

※ Click on the image to enlarge.

「 FB-101」

Reversible treatment effect on fibrosis

FNCT Biotech’s paradigm
  • CSF3 is the upstream pathway that regulates all the pivotal fibrosis pathways. 
  • regulates the TGF-β pathway and modulates myofibrogenesis and ECM deposition through reciprocal cooperation with TGF-β. 
  • promotes ECM accumulation by stabilizing collagen through the upregulation of prolyl-hydroxylase. 
  • A positive feedback loop between CSF3 and TGF-β1 plays a significant role in the progression of idiopathic pulmonary fibrosis.
FNCT BIOTECH is 

advancing a novel antibody-based therapy for pulmonary fibrosis, a disease with significant unmet medical needs. With proof of concept (PoC) established and a clearly defined mechanism of action (MoA), our treatment candidate has demonstrated strong therapeutic potential. Upon successful development, it is poised to become a game changer in pulmonary fibrosis care, offering substantial clinical impact and commercial value. 


"Once fully developed, it is expected to revolutionize pulmonary fibrosis care, delivering significant clinical benefits and strong commercial potential." 

Mode of Action of FB-101
The current paradigm of fibrosis mechanism
  • TGF-β, a widely recognized key regulator of fibrosis, is a primary target in developing antifibrotic therapies 
  • For these reasons, various molecules that mediate downstream signaling of TGF-β have also emerged as important targets for anti-fibrotic drug development.
FNCT Biotech’s paradigm
  • CSF3 is the upstream pathway that regulates all the pivotal fibrosis pathways. 
  • regulates the TGF-β pathway and modulates myofibrogenesis and ECM deposition through reciprocal cooperation with TGF-β. 
  • promotes ECM accumulation by stabilizing collagen through the upregulation of prolyl-hydroxylase. 
  • A positive feedback loop between CSF3 and TGF-β1 plays a significant role in the progression of idiopathic pulmonary fibrosis.

「 FB-101」

Reversible treatment effect on fibrosis

Fnct Biotech logo

E-mail

fnct@fnctbiotech.com

Headquarter/R&D Center 

Chungmuro New Building Rm 201/226, 2, Toegye-ro 36-gil, Jung-gu, Seoul, Republic of Korea

Virginia Office 

12020 Sunrise Valley Drive, Suite 100, Reston, VA 20191, USA

Copyright ⓒ FNCT BIOTECH All Rights Reserved.

Fnct Biotech logo

E-mail

fnct@fnctbiotech.com

Headquarter/R&D Center
Chungmuro New Building Rm 201/226, 2, Toegye-ro 36-gil, Jung-gu, Seoul, Republic of Korea
Virginia Office 
12020 Sunrise Valley Drive, Suite 100, Reston, VA 20191, USA

Copyright ⓒ FNCT BIOTECH All Rights Reserved.